Carmignac Gestion Grows Holdings in McKesson Corporation $MCK

Posted by Francis Steltz on Sep 8th, 2026

Carmignac Gestion lifted its stake in shares of McKesson Corporation (NYSE:MCK – Free Report) by 97.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 626,904 shares of the company’s stock after buying an additional 309,183 shares during the quarter. McKesson comprises 6.1% of Carmignac Gestion’s portfolio, making the stock its 4th largest position. Carmignac Gestion owned approximately 0.54% of McKesson worth $473,674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in McKesson by 46.3% during the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after buying an additional 798 shares during the period. Caxton Associates LLP bought a new stake in McKesson during the first quarter worth about $233,000. Sivia Capital Partners LLC grew its holdings in McKesson by 77.9% in the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock worth $502,000 after purchasing an additional 300 shares during the period. Treasurer of the State of North Carolina raised its stake in McKesson by 0.9% during the second quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company’s stock valued at $42,958,000 after buying an additional 508 shares during the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in shares of McKesson in the 2nd quarter worth about $166,000. Institutional investors own 85.07% of the company’s stock.

McKesson Trading Down 2.2%

MCK stock traded down $20.34 during trading on Tuesday, reaching $887.65. The stock had a trading volume of 747,838 shares, compared to its average volume of 949,302. The stock’s 50 day moving average is $853.90 and its two-hundred day moving average is $841.76. The firm has a market cap of $103.49 billion, a PE ratio of 23.75, a PEG ratio of 1.81 and a beta of 0.30. McKesson Corporation has a 52 week low of $687.68 and a 52 week high of $999.00.

McKesson (NYSE:MCK – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping the consensus estimate of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm had revenue of $105.38 billion for the quarter, compared to analysts’ expectations of $103.88 billion. During the same quarter in the prior year, the business earned $8.26 EPS. The business’s quarterly revenue was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, research analysts anticipate that McKesson Corporation will post 44.65 EPS for the current year.

McKesson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. This is a boost from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date is Tuesday, September 1st. McKesson’s dividend payout ratio (DPR) is presently 10.06%.

Insider Transactions at McKesson

In other news, Director Bradley E. Lerman sold 301 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brian S. Tyler sold 8,463 shares of McKesson stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the transaction, the chief executive officer owned 5,919 shares in the company, valued at approximately $4,697,081.64. This trade represents a 58.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 17,227 shares of company stock worth $13,544,415. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MCK. Morgan Stanley reiterated an “overweight” rating on shares of McKesson in a research note on Friday, August 7th. Evercore reaffirmed an “outperform” rating on shares of McKesson in a research report on Thursday, August 6th. Barclays increased their target price on McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday. Finally, UBS Group increased their price objective on McKesson from $1,050.00 to $1,080.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $973.44.

Get Our Latest Stock Report on McKesson

About McKesson

(Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.